Three GOP Attorneys General Sue DOJ Over Cannabis Rescheduling

Attorneys general from Indiana, Nebraska, and Louisiana filed a federal lawsuit this week challenging the Trump administration's decision to reschedule cannabis from Schedule I to Schedule III—a move that marks an unusual clash between Republican state officials and a GOP administration.

The three Republican AGs argue in their complaint that the Department of Justice's rescheduling action "fails to comport with the requirements" of the Controlled Substances Act and administrative law. The lawsuit targets DOJ's implementation of the policy announced last month, which would represent the most significant shift in federal cannabis policy in over 50 years.

"This agency action was arbitrary and capricious," the complaint states, setting up what could become a protracted legal battle over the federal government's authority to reclassify marijuana.

The Legal Challenge

The lawsuit centers on procedural and substantive objections to how DOJ executed the rescheduling. Indiana Attorney General Todd Rokita, Nebraska Attorney General Mike Hilgers, and Louisiana Attorney General Liz Murrill claim the administration rushed the process without adequate scientific review or public comment periods required under federal administrative law.

The filing comes despite the Trump administration's stated position that rescheduling would reduce federal interference in state-legal cannabis programs. But the three states—all of which maintain strict prohibitionist policies—view the move as federal overreach that could undermine their own enforcement efforts.

Policy experts suggest the lawsuit faces significant hurdles. "The Controlled Substances Act gives the Attorney General broad discretion to reschedule drugs based on scientific and medical findings," said Robert Mikos, a Vanderbilt Law professor who specializes in drug policy. "The question is whether DOJ followed proper procedure, not whether these states agree with the policy outcome."

Industry Implications

The legal challenge injects uncertainty into an already complex regulatory transition. Cannabis companies had been preparing for Schedule III status, which would eliminate the 280E tax burden that currently prevents them from deducting normal business expenses. Industry analysts estimate this change could save multi-state operators hundreds of millions of dollars annually.

"We're watching this closely," said Aaron Smith, co-founder of the National Cannabis Industry Association. "Any delay in rescheduling prolongs the unsustainable tax situation our members face."

The lawsuit also highlights the fractured Republican position on cannabis policy. While Trump has positioned himself as supportive of state-level legalization and industry growth, social conservatives in states like Indiana and Nebraska remain firmly opposed to any federal policy shift that could normalize marijuana use.

What's Next

The case will likely be assigned to a federal district court in the coming weeks. Legal observers expect the states to seek a preliminary injunction to halt the rescheduling process while the case proceeds—a request that could determine whether the policy change moves forward on schedule or faces indefinite delay.

DOJ has not yet filed its response to the complaint. The department has 60 days to answer the lawsuit and will likely argue that the rescheduling followed proper scientific review and administrative procedures.

Meanwhile, the Drug Enforcement Administration continues its own evaluation of the rescheduling decision, as required under the Controlled Substances Act. DEA Administrator Anne Milgram has not publicly commented on the lawsuit.

The timeline for resolution remains unclear, but similar administrative law challenges typically take 12 to 18 months to reach final judgment. That means the cannabis industry could face extended uncertainty about its federal tax status and regulatory framework well into 2026.

---

This article is based on original reporting by www.marijuanamoment.net.